T1	DISO 75 80	polio
#1	AnnotatorNotes T1	C0032371; Poliomyelitis; Disease or Syndrome
T2	PROC 168 180	erradicación
#2	AnnotatorNotes T2	C3178994; Disease Eradication; Health Care Activity
T3	DISO 187 200	poliomielitis
#3	AnnotatorNotes T3	C0032371; Poliomyelitis; Disease or Syndrome
T4	DISO 265 270	polio
#4	AnnotatorNotes T4	C0032371; Poliomyelitis; Disease or Syndrome
T5	PROC 433 465	evaluación de la reactogenicidad
T6	DISO 482 487	polio
#5	AnnotatorNotes T6	C0032371; Poliomyelitis; Disease or Syndrome
T7	PROC 524 545	estudio multicéntrico
#6	AnnotatorNotes T7	C1096776; Multicenter Study; Research Activity
T8	DISO 963 968	polio
#7	AnnotatorNotes T8	C0032371; Poliomyelitis; Disease or Syndrome
T9	PROC 788 802	consentimiento
#8	AnnotatorNotes T9	C0567423; Informed consent for procedure; Therapeutic or Preventive Procedure
T10	PROC 1137 1171	administró por la vía intradérmica
#9	AnnotatorNotes T10	C0812147; Medication administration: intradermal; Therapeutic or Preventive Procedure
T11	DISO 1213 1218	polio
#10	AnnotatorNotes T11	C0032371; Poliomyelitis; Disease or Syndrome
T12	CONC 1236 1254	cara anterolateral
T13	ANAT 1259 1274	muslo izquierdo
T14	DISO 1508 1524	eventos adversos
#11	AnnotatorNotes T14	C0877248; Adverse event; Pathologic Function
T15	PROC 1634 1659	reactogenicidad se evaluó
#12	AnnotatorNotes T15	C5420740; Reactogenicity Study; Research Activity
T16	PROC 1743 1754	observación
#13	AnnotatorNotes T16	C0302523; Observation in research; Research Activity
T17	DISO 1762 1778	eventos adversos
#14	AnnotatorNotes T17	C0877248; Adverse event; Pathologic Function
T18	PROC 1874 1883	protocolo
#15	AnnotatorNotes T18	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T19	DISO 1919 1935	eventos adversos
#16	AnnotatorNotes T19	C0877248; Adverse event; Pathologic Function
T20	DISO 1973 1992	reacciones adversas
#17	AnnotatorNotes T20	C0041755; Adverse reaction to drug; Pathologic Function | C0559546; Adverse reactions; Pathologic Function | C0879626; Adverse effects; Pathologic Function
T21	DISO 2021 2031	induración
#18	AnnotatorNotes T21	C0332534; Induration; Pathologic Function
T22	DISO 2041 2083	enrojecimiento en el sitio de la inyección
#19	AnnotatorNotes T22	C0581287; Injection site erythema; Disease or Syndrome
T23	ANAT 2062 2083	sitio de la inyección
T24	DISO 2146 2151	polio
#20	AnnotatorNotes T24	C0032371; Poliomyelitis; Disease or Syndrome
T25	PROC 31 58	administración intradérmica
#21	AnnotatorNotes T25	C0812147; Medication administration: intradermal; Therapeutic or Preventive Procedure
T26	CHEM 65 91	vacuna de polio inactivada
#22	AnnotatorNotes T26	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T27	CHEM 255 281	vacuna de polio inactivada
#23	AnnotatorNotes T27	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T28	CHEM 472 498	vacuna de polio inactivada
#24	AnnotatorNotes T28	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T29	PROC 589 659	Fase I-II de un ensayo clínico controlado, aleatorio y a simple ciegas
#25	AnnotatorNotes T29	C0282460; Phase 2 Clinical Trials; Research Activity + C0206035; Controlled Clinical Trials, Randomized; Research Activity + C0150108; Blinded; Research Activity
T30	CHEM 953 979	vacuna de polio inactivada
#26	AnnotatorNotes T30	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T31	CHEM 1203 1229	vacuna de polio inactivada
#27	AnnotatorNotes T31	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T32	CHEM 1623 1629	vacuna
#28	AnnotatorNotes T32	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	DISO 2033 2038	dolor
#29	AnnotatorNotes T33	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T34	PROC 2074 2083	inyección
#30	AnnotatorNotes T34	C1533685; Injection procedure; Therapeutic or Preventive Procedure
T35	CHEM 2136 2162	vacuna de polio inactivada
#31	AnnotatorNotes T35	C0718003; Poliovirus Vaccine, Inactivated; Immunologic Factor · Pharmacologic Substance
T36	Route 46 58	intradérmica
#32	AnnotatorNotes T36	C1522475; Intradermal Route of Drug Administration; Functional Concept
T37	DEVI 99 117	inyector sin aguja
#33	AnnotatorNotes T37	C4725395; Needle-free Injector; Medical Device
T40	LIVB 668 677	lactantes
#34	AnnotatorNotes T40	C0021270; Infant; Age Group
T42	Date 726 731	julio
T43	Date 734 748	agosto de 2006
T44	LIVB 768 774	padres
#35	AnnotatorNotes T44	C0030551; parent; Family Group
T45	LIVB 881 886	niños
#36	AnnotatorNotes T45	C0008059; Child; Age Group
T46	Duration 900 922	las 6, 10 y 14 semanas
T47	PHYS 927 937	nacimiento
#37	AnnotatorNotes T47	C0005615; Birth; Organism Function | C1148523; Childbirth; Organism Function
T48	Dose 939 949	tres dosis
T49	Route 1155 1171	vía intradérmica
#38	AnnotatorNotes T49	C1522475; Intradermal Route of Drug Administration; Functional Concept
T50	Dose 1175 1199	dosis reducida de 0,1 mL
T52	DEVI 1289 1307	inyector sin aguja
#39	AnnotatorNotes T52	C4725395; Needle-free Injector; Medical Device
T55	Date 1319 1323	2000
T56	LIVB 1328 1341	grupo control
#40	AnnotatorNotes T56	C0009932; Control Groups; Group
T57	Dose 1370 1376	0,5 mL
T58	Route 1384 1401	vía intramuscular
#41	AnnotatorNotes T58	C1556154; Intramuscular Route of Drug Administration; Functional Concept
T59	DEVI 1466 1488	jeringuilla prellenada
#42	AnnotatorNotes T59	C3273587; Pre-filled Syringe; Manufactured Object
T61	Duration 1533 1564	la primera hora, 24, 48, y 72 h
T63	LIVB 1813 1818	niños
#43	AnnotatorNotes T63	C0008059; Child; Age Group
T64	Neg_cue 1902 1904	No
T65	Route 2179 2196	vía intramuscular
#44	AnnotatorNotes T65	C1556154; Intramuscular Route of Drug Administration; Functional Concept
T66	Route 2236 2252	vía intradérmica
#45	AnnotatorNotes T66	C1522475; Intradermal Route of Drug Administration; Functional Concept
T67	DEVI 2259 2278	inyector sin agujas
#46	AnnotatorNotes T67	C4725395; Needle-free Injector; Medical Device
T38	Duration 1591 1603	los 7 y 30 d
T39	LIVB 1680 1688	pediatra
#47	AnnotatorNotes T39	C0237433; Pediatrician (occupation); Professional or Occupational Group
T53	LIVB 1713 1730	médico de familia
#48	AnnotatorNotes T53	C1704221; Physicians, Family; Professional or Occupational Group
T54	LIVB 687 698	ambos sexos
#49	AnnotatorNotes T54	C0025266; Male population group; Population Group + C0043210; Woman; Population Group
A1	Population_data T63 Age
A2	Population_data T40 Age
A3	Population_data T45 Age
A4	Assertion T19 Negated
R1	Negation Arg1:T64 Arg2:T19	
T41	DISO 1 16	Reactogenicidad
#50	AnnotatorNotes T41	C5552969; Reactogenicity; Pathologic Function
R2	Causes Arg1:T25 Arg2:T41	
R3	Has_Route_or_Mode Arg1:T26 Arg2:T36	
R4	Used_for Arg1:T26 Arg2:T25	
R5	Used_for Arg1:T37 Arg2:T25	
T51	DISO 450 465	reactogenicidad
#51	AnnotatorNotes T51	C5552969; Reactogenicity; Pathologic Function
R6	Causes Arg1:T28 Arg2:T51	
R7	Used_for Arg1:T27 Arg2:T2	
T60	Quantifier_or_Qualifier 678 683	sanos
#52	AnnotatorNotes T60	C3898900; Healthy; Qualitative Concept
R8	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T60	
R9	Before Arg1:T9 Arg2:T29	
R10	Before Arg1:T9 Arg2:T7	
T62	Observation 821 862	cumplieron con los criterios de inclusión
#53	AnnotatorNotes T62	C1302261; Patient eligible for clinical trial; Finding (?)
R17	Has_Quantifier_or_Qualifier Arg1:T54 Arg2:T60	
R18	Experiences Arg1:T45 Arg2:T47	
R20	After Arg1:T30 Arg2:T46	
R21	Before Arg1:T47 Arg2:T30	
R22	Has_Dose_or_Strength Arg1:T30 Arg2:T48	
R23	Experiences Arg1:T45 Arg2:T30	
R24	Has_Route_or_Mode Arg1:T31 Arg2:T49	
R25	Has_Dose_or_Strength Arg1:T31 Arg2:T50	
R26	Used_for Arg1:T31 Arg2:T10	
#54	AnnotatorNotes T13	C0230426; Structure of left thigh; Body Part, Organ, or Organ Component | C1279549; Entire left thigh; Body Part, Organ, or Organ Component
#55	AnnotatorNotes T12	C0332194; Anterolateral; Spatial Concept
R28	Location_of Arg1:T13 Arg2:T10	
R29	Location_of Arg1:T12 Arg2:T10	
R30	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T12	
R27	Used_for Arg1:T52 Arg2:T10	
T68	CONC 1355 1360	dosis
#56	AnnotatorNotes T68	C0178602; Dosage; Quantitative Concept
R31	Has_Quantifier_or_Qualifier Arg1:T68 Arg2:T57	
T69	Quantifier_or_Qualifier 1402 1410	profunda
#57	AnnotatorNotes T69	C0205125; Deep (qualifier value); Spatial Concept
R32	Has_Quantifier_or_Qualifier Arg1:T58 Arg2:T69	
R33	Experiences Arg1:T56 Arg2:T59	
R34	Has_Duration_or_Interval Arg1:T14 Arg2:T61	
R35	Has_Duration_or_Interval Arg1:T14 Arg2:T38	
R36	After Arg1:T14 Arg2:T32	
T70	DISO 1634 1649	reactogenicidad
#58	AnnotatorNotes T70	C5552969; Reactogenicity; Pathologic Function
T71	Observation 1859 1883	finalizaron el protocolo
#59	AnnotatorNotes T71	C0580352; Treatment completed; Finding (?)
T72	Quantifier_or_Qualifier 1936 1945	moderados
A5	Assertion T72 Negated
#60	AnnotatorNotes T72	C2945599; Mild (qualifier value); Qualitative Concept
R41	Negation Arg1:T64 Arg2:T72	
T73	Quantifier_or_Qualifier 1948 1954	serios
A6	Assertion T73 Negated
#61	AnnotatorNotes T73	C1547227; Severe - Severity of Illness Code; Intellectual Product
R42	Negation Arg1:T64 Arg2:T73	
R43	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T72	
R44	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T73	
R45	Causes Arg1:T34 Arg2:T22	
R46	Location_of Arg1:T23 Arg2:T22	
#62	AnnotatorNotes T23	C0229986; Application site; Anatomical Structure
R47	Causes Arg1:T34 Arg2:T33	
R48	Causes Arg1:T34 Arg2:T21	
R49	Causes Arg1:T34 Arg2:T20	
T74	Quantifier_or_Qualifier 1993 2000	locales
#63	AnnotatorNotes T74	C0205276; Local; Spatial Concept
R50	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T74	
R51	Has_Route_or_Mode Arg1:T35 Arg2:T65	
R52	Has_Route_or_Mode Arg1:T35 Arg2:T66	
R54	Has_Route_or_Mode Arg1:T59 Arg2:T58	
T75	Quantifier_or_Qualifier 2001 2008	menores
#64	AnnotatorNotes T75	C0205165; Minor (value); Qualitative Concept
R55	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T75	
R56	Used_for Arg1:T67 Arg2:T35	
T76	PHYS 699 706	nacidos
#65	AnnotatorNotes T76	C0005615; Birth; Organism Function | C1148523; Childbirth; Organism Function
R15	Experiences Arg1:T54 Arg2:T76	
R16	Experiences Arg1:T40 Arg2:T76	
R11	After Arg1:T76 Arg2:T42	
R12	Before Arg1:T76 Arg2:T43	
#66	AnnotatorNotes T5	C5420740; Reactogenicity Study; Research Activity
A7	Experiencer T40 Patient
A8	Experiencer T54 Patient
A9	Experiencer T44 Family_member
A10	Experiencer T45 Patient
A11	Experiencer T56 Patient
A12	Experiencer T39 Other
A13	Experiencer T53 Other
A14	Experiencer T63 Patient
